Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

MaxCyte Inc

Healthcare GB MXCT

NoneGBX
0.00(0%)

Last update at 2026-06-04T16:08:13.064693Z

Day Range

--
LowHigh

52 Week Range

0.642.96
LowHigh

Fundamentals

  • Previous Close 1.23
  • Market Cap161.75M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-46.91700M
  • Revenue TTM37.67M
  • Revenue Per Share TTM0.36
  • Gross Profit TTM 30.48M
  • Diluted EPS TTM-0.3

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31
Income before tax -41.05500M -37.92300M -37.45460M -32.63670M -30.38510M
Minority interest - - - - -
Net income -41.05500M -37.92300M -37.45460M -32.63670M -30.38510M
Selling general administrative 29.69M 30.07M 52.79M 49.87M 47.81M
Selling and marketing expenses 26.66M 26.98M - - -
Gross profit 31.53M 36.55M 33.33M 35.39M 36.21M
Reconciled depreciation 4.79M 4.17M 3.99M 3.65M 3.17M
Ebit -51.19700M -48.29900M - - -
Ebitda -46.40700M -44.12800M - - -
Depreciation and amortization 4.79M 4.17M - - -
Non operating income net other - - - - -
Operating income -51.19700M -48.29900M -46.95350M -40.71310M -36.37860M
Other operating expenses 89.82M 89.59M - - -
Interest expense - - - - -
Tax provision 0.00000M 0.00000M - - -
Interest income 10.14M 10.38M 9.51M 8.20M 6.12M
Net interest income 10.14M 10.38M 9.38M 8.08M 5.99M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 4.00M - - -
Total revenue 38.63M 41.29M 38.05M 40.69M 41.25M
Total operating expenses 82.72M 84.84M 85.00M 81.40M 77.63M
Cost of revenue 7.10M 4.74M 4.72M 5.29M 5.04M
Total other income expense net 10.14M 10.38M - - -
Discontinued operations - - - - -
Net income from continuing ops -41.05500M -37.92300M -37.45460M -32.63670M -30.38510M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 239.47M 268.27M 286.65M 284.12M 51.78M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.61M 3.90M 2.78M 3.31M 1.00M
Total liab 33.22M 36.11M 32.69M 21.22M 18.55M
Total stockholder equity 206.25M 232.17M 253.97M 262.90M 33.23M
Deferred long term liab - - - - -
Other current liab 8.30M 11.27M 8.03M 6.52M 5.21M
Common stock 1.06M 1.04M 1.02M 1.01M 0.77M
Capital stock 1.06M 1.04M 1.02M 1.01M 0.77M
Retained earnings -216.85300M -175.79800M -137.87530M -114.30450M -95.22230M
Other liab - - 1.32M 0.45M 0.65M
Good will - - - - -
Other assets - - 0.81M 0.32M 0.03M
Cash 27.88M 46.51M 11.06M 47.78M 18.76M
Cash and equivalents - - - - -
Total current liabilities 15.78M 17.86M 15.43M 15.62M 11.61M
Current deferred revenue 5.25M 5.07M 6.71M 6.75M 4.84M
Net debt -9.85000M -27.76300M 5.03M -42.10030M -11.78880M
Short term debt 0.86M 0.77M 0.16M 0.53M 0.67M
Short long term debt - - - - -
Short long term debt total 18.03M 18.74M 16.09M 5.68M 6.97M
Other stockholder equity 422.05M 406.93M 390.82M 376.19M 127.67M
Property plant equipment - - 33.58M 13.37M 6.49M
Total current assets 171.68M 190.19M 252.27M 270.43M 45.25M
Long term investments 35.78M 42.94M - - -
Net tangible assets - - 253.97M 262.90M 33.23M
Short term investments 126.60M 121.78M 216.27M 207.26M 16.01M
Net receivables 4.68M 5.78M 13.57M 6.88M 5.17M
Long term debt - - - - 4.92M
Inventory 8.91M 12.23M 8.58M 5.20M 4.32M
Accounts payable 1.36M 0.74M 0.53M 1.82M 0.89M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -2.97570M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.77M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.53M 0.39M 0.81M 0.32M 0.03M
Deferred long term asset charges - - - - -
Non current assets total 67.79M 78.08M 34.39M 13.69M 6.53M
Capital lease obligations 18.03M 18.74M 16.09M 5.68M 2.05M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31
Investments 6.93M 54.98M 32.03M -31.45830M -189.98300M
Change to liabilities - - - - -
Total cashflows from investing activities 6.93M 54.98M - - -
Net borrowings - - - - -
Total cash from financing activities 2.06M 2.14M 2.88M 3.28M 3.45M
Change to operating activities - - - - -
Net income -41.05500M -37.92300M -37.45460M -32.63670M -30.38510M
Change in cash -18.62200M 35.44M 6.15M -54.61150M -201.94390M
Begin period cash flow 46.51M 11.06M 43.02M 109.17M 239.78M
End period cash flow 27.88M 46.51M 49.17M 54.56M 37.83M
Total cash from operating activities -27.61000M -21.68600M -28.75400M -26.43690M -15.41340M
Issuance of capital stock - 0.27M - - -
Depreciation 4.79M 4.17M 3.99M 3.65M 3.17M
Other cashflows from investing activities - 0.00900M - - -
Dividends paid - - - - -
Change to inventory 1.36M -4.53400M -4.70020M -3.39550M -3.82230M
Change to account receivables 1.23M 7.14M -0.17890M 0.07M 1.46M
Sale purchase of stock - - - - -
Other cashflows from financing activities 2.06M 1.87M - - -
Change to netincome - - - - -
Capital expenditures 1.65M 3.70M 4.98M 7.74M 14.04M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.75100M 3.82M -2.50810M -4.92150M 3.40M
Stock based compensation 13.08M 13.98M 13.52M 13.11M 12.57M
Other non cash items -3.67700M -5.73300M 0.09M 0.09M 0.06M
Free cash flow -29.26100M -25.38600M -33.73380M -34.17430M -29.44910M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MXCT
MaxCyte Inc		 - -% - - - 4.29 1.16 2.94 -9.2094
SN
Smith & Nephew PLC		 24.00 2.17% 1132.50 23.24 12.47 1.70 2.59 2.67 10.76
NIOX
NIOX Group PLC		 1.80 2.95% 62.80 28.20 18.73 4.84 3.41 4.35 13.85
EKF
EKF Diagnostics Holdings Plc		 -0.15 0.57% 26.25 - 34.97 2.02 1.46 1.72 7.01
CREO
Creo Medical Group PLC		 -0.25 1.82% 13.50 - - 199.36 0.74 6.21 8.16

Reports Covered

Stock Research & News

View All

Profile

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

MaxCyte Inc

9713 Key West Avenue, Rockville, MD, United States, 20850

Key Executives

Name Title Year Born
Mr. Douglas Arthur Doerfler Founder, Pres, CEO & Exec. Director 1956
Mr. Ronald Evan Holtz CPA, Ph.D. Chief Financial Officer 1958
Dr. J. Stark Thompson Ph.D. Consultant 1942
Dr. Cenk Sumen Chief Scientific Officer 1973
Mr. Sean Menarguez Director of Investor Relations NA
Mr. Maher Masoud Exec. VP, Gen. Counsel & Sec. 1975
Mr. Thomas Michael Ross Exec. VP of Global Sales 1961
Dr. James Brady Ph.D. Sr. VP of Technical Applications & Customer Support NA
Dr. Sarah Haecker Meeks Ph.D. Sr. VP of Bus. Devel. NA
Mr. James Lovgren Sr. VP of Global Marketing NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions